Lipids and diabetes

Georg P, Ludvik B

Homepage:

www.kup.at/jcbc

Online Data Base Search for Authors and Keywords
Lipids and Diabetes

P. Georg, B. Ludvik

Atherosclerosis is a major complication of diabetes being responsible for the increased morbidit and mortality in these patients. Diabetic dyslipidaemia comprises elevated triglyceride levels as well as decreased HDL cholesterol levels. LDL cholesterol is quantitatively not significantly different from non-diabetic subjects, however, there is a preponderance of small dense LDL particles with a greater susceptibility to oxidation. Epidemiological studies have shown that patients with type-2 diabetes mellitus with no history of cardiovascular disease, have the same risk for cardiac events as non-diabetic patients with pre-existing coronary disease have. The increased incidence of cardiovascular disease (CVD) in diabetes, the greater case fatality and 1-year mortality in patients with myocardial infarction strongly suggest that preventive lipid lowering therapy is of great importance. Unfortunately, the rationale for prevention of CVD in patients with diabetes is obtained only from pathophysiological evidence, interventional studies in non-diabetic populations and post-hoc subgroup analyses in diabetic patients. Therefore, many questions regarding the therapy of diabetic dyslipidaemia still remain open. However, these studies suggest that lowering cholesterol in patients with type-2 diabetes is at least as effective as in a non-diabetic population. Results from prospective lipid lowering trials in patients with diabetes are therefore awaited with great interest. J Clin Basic Cardiol 2000; 3: 159–62.

Key words: atherosclerosis, cardiovascular mortality, statins, fibrates

Diabetic dyslipidaemia

In type-2 diabetic patients quantitative and qualitative abnormalities in lipoproteins are presumed to be responsible for the increased risk of macrovascular disease. Each lipid and lipoprotein fraction is affected by insulin resistance and hyperglycaemia [7, 8]. The common pattern of dyslipidaemia in type-2 diabetic patients shows elevated triglyceride levels and decreased HDL cholesterol levels. The concentration of LDL cholesterol is usually not significantly different from non-diabetic subjects. Diabetic patients may have elevated levels of non-HDL cholesterol (LDL plus VLDL). However, type-2 diabetic patients typically have a preponderance of small, dense LDL particles, which possibly increases atherogenicity by a greater susceptibility to oxidation even if the absolute concentration of LDL cholesterol is not significantly increased. Hypertriglyceridaemia often is rather modest. The median triglyceride level in type-2 diabetic patients is < 2.3 mmol/l (200 mg/dl), and 85–95 % of patients have triglyceride levels below 4.5 mmol/l (400 mg/dl) [9].

As in non-diabetic individuals, lipid levels may be affected by factors unrelated to hyperglycaemia or insulin resistance, such as renal disease, hypothyroidism, and genetically determined lipoprotein disorders. Abuse of alcohol and estrogen replacement therapy may also contribute to hypertriglyceridaemia.

In well-controlled patients with type-1 diabetes there is only a small difference in plasma lipid levels compared with non-diabetic subjects. However, noticeable abnormalities in lipoprotein composition are observed in these patients despite good glycaemic control and near normal plasma lipid levels [10, 11].

Hyperglycaemia

Hyperglycaemia is a cardiovascular risk factor [12–14] possibly because of non-enzymatic glycation of proteins [15] and lipoproteins, which increases their atherogenetic potency. There is evidence that advanced glycation end products enhance the vulnerability of arteries [16]. Many studies have shown that hyperinsulinaemia due to insulin resistance represents an increased risk of atherosclerosis [17–20]. Regarding diabetes control, a level of haemoglobin A1c > 6.2 % is presumed to elevate the risk of cardiovascular disease as reported in some studies [21, 22]. The UKPDS could demonstrate an increased cardiovascular risk of 11 % for each increment of 1 % in haemoglobin A1c.

Blood pressure

Increased blood pressure is a major risk factor for cardiovascular disease particular in diabetic subjects. In the UKPDS, a 15 % increased risk for cardiovascular disease was reported for an elevation in systolic blood pressure of 10 mmHg, which was similar to that reported in the general population [23].

Other risk factors

In fact, all factors that increase the risk of atherosclerotic vascular disease in non-diabetic subjects also do so in diabetic patients. These factors include smoking, increased levels of homocystein and several coagulation abnormalities.

Plasma Lipids and Cardiovascular Disease

Total and LDL-Cholesterol

The association between plasma total cholesterol and CVD risk is well established. Results from a 12 year follow up of 316,099 men screened for the Multiple Risk Factor Interven-
Lipids and Diabetes

Lipid Reduction and Cardiovascular Disease in Type-2 Diabetes Mellitus

Lipid intervention trials in diabetes – *post hoc* analyses

No prospective clinical trials have been performed on the effects of lipid lowering therapy for the prevention of CVD focused on diabetic patients. However, a number of large clinical trials have also included a small NIDDM population. The Helsinki Heart Study, a primary intervention study, examined the effect of treating hyperlipidaemia with gemfibrocil in middle-aged men [32]. Individuals treated with gemfibrocil had fewer cardiac events (3.4 % of diabetic patients) than those in the placebo group (10.5 % of diabetic patients). However, the diabetic study population of 135 patients was too small to make the difference statistically significant [33].

The other two studies, the Cholesterol and Recurrent Events (CARE) trial [34, 35] and the Scandinavian Simvastatin Survival Study (4S) [36] were secondary intervention studies using pravastatin or simvastatin, respectively, both drugs from the hydroxymethylglutaryl-CoA-reductase inhibitor group. The CARE study included 856 patients with pre-existing type-2 diabetes mellitus. Major coronary events occurred in 37 % of diabetic patients receiving placebo and 29 % of patients receiving pravastatin, with a relative risk reduction of 25 %. The 4S study included 202 patients with type-2 diabetes, randomized to simvastatin treatment or placebo, respectively. In the placebo treatment group, major coronary events occurred in 63 % compared with 25 % in the simvastatin group. The relative CVD risk reduction in 4S was 55 %.

Despite limitations in patient enrolment and small population numbers, these studies suggest that treatment of hypercholesterolaemia in diabetic patients will reduce the risk of recurrent cardiac events in individuals with pre-existing coronary artery disease at least to the same extent as in a non-diabetic population.

Ongoing lipid intervention trials in diabetes

There are no published data from studies designed to examine the effects of lipid intervention on coronary artery disease specifically in diabetes. Based on the analyses of the effects of lipid lowering substances in diabetic subpopulations, several studies are currently under way. The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study examines the effect of treatment with fenofibrate on total and fatal coronary disease events in type 2 diabetic men and women. Some subjects of the population will have a pre-existing CVD. There are following lipid entry criteria: triglyceride > 1.0 mmol/l and total cholesterol < 6.0 mmol/l or < 6.5 mmol/l for subjects with preexisting coronary heart disease. Another study, the Collaborative Atorvastatin Diabetes Study (CARDS), investigates the effects of a minimum of 4 years treatment with atorvastatin versus placebo in 2120 patients with type-2 diabetes and no cardiovascular disease in their medical history. The lipid entry criteria are: triglyceride < 4.14 mmol/l and LDL-cholesterol < 4.14 mmol/l. The Atorvastatin Study for the Prevention of End-points in NIDDM (ASPEN) will recruit 2250 diabetic patients for treatment with 10 mg of atorvastatin vs. placebo. In the Lipids in Diabetes Study (LDS) 5000 diabetic patients with normal or near normal lipid levels without evidence of cardiovascular disease will be randomized to 0.4 mg of cerivastatin or to 200 mg of micronized fenofibrate or to a combination of both drugs compared with placebo in a “2 × 2” factorial design with a follow up of 4–5 years.

Nearly completed is the Diabetes Atherosclerosis Intervention Study (DAIS) [37]. The primary aim of the study is...
to investigate whether long-term treatment (minimum of 3 years) with micronized fenofibrate will alter the regression or the progression of the coronary artery disease determined by angiography in men and women with type-2 diabetes [38]. Allowed lipid entry criteria are mild hypercholesterolaemia, mild hypertriglyceridaemia, or both. Results from the MRC/BHF Heart Protection Study [39] with 40 mg simvastatin daily or placebo are also expected soon. The study has randomized about 6000 patients with diabetes, 4000 of them without evidence of cardiovascular disease at entry. Another large population of 3500 patients with type-2 diabetes and hypertension is included in the large Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) [40]. The Anglo Scandinavian Cardiac Outcomes Trial (ASCOT) is currently recruiting [41].

The results from a finished secondary prevention VA HDL cholesterol Interventional Trial of gemfibrocil, which randomized about 600 patients with diabetes, are awaited with interest [42].

**Management of Dyslipidaemia in Adults with Diabetes**

First line agents, which should be used in patients with diabetic dyslipidaemia featuring hypercholesterolaemia are statins. They are well tolerated and decrease the LDL cholesterol levels by 25–55 %, depending on the statin used and dosage. The optimal LDL cholesterol levels for adults with diabetes are < 2.6 mmol/l (100 mg/dl), optimal HDL cholesterol levels are > 1.15 mmol/l (45 mg/dl), and desirable triglyceride levels are < 2.30 mmol/l (200 mg/dl). Higher doses of statins may also be moderately effective in reducing the triglyceride level and therefore reduce the need for a combination therapy. The fibric acid derivatives are more effective in decreasing the triglyceride levels and raising the HDL-cholesterol levels, but do not substantially change the LDL-cholesterol levels. The combination of a statin and fibrate might be particularly effective, because of complimentary effects on the lipid profile, but these drugs have not typically been used together due to the risk of myopathy. However, the large statin trials have not shown an increased risk of myopathy. The large statins may also be moderately effective in reducing the triglyceride level and therefore reduce the need for a combination therapy [43].

Type-1 diabetic patients tend to have normal lipoprotein levels. Their composition of lipoproteins may be abnormal, but the effects of these abnormalities on CVD have not been investigated in clinical trials. There are only few data from observational studies on lipoproteins and CVD in type 1 diabetic patients. In spite of the lack of data, if these patients have LDL cholesterol levels above the goals recommended for type 2 diabetic patients, they should be aggressively treated [44].

**Conclusion**

Atherosclerosis is a major complication of diabetes. Studies indicate that patients with type-2 diabetes mellitus who have no history of cardiovascular disease, have the same risk for cardiac events as do non-diabetic patients with pre-existing coronary disease [45]. The increased incidence of CVD in diabetes, the greater case fatality and 1-year mortality in patients with myocardial infarction [5] strongly suggest that preventive lowering of lipid levels, potentially to goals accepted for secondary prevention, is of great importance. Unfortunately, the rationale for prevention of CVD in patients with diabetes is obtained only from the pathophysiological evidence, from interventional studies in non-diabetic populations and from post-hoc subgroup analyses in diabetic patients. Therefore, many questions regarding the management of blood lipid levels in diabetes still remain open. When should the treatment be started? Should the treatment be based on CVD risk, on lipid levels or other factors? How low should be the target level of cholesterol? For those patients with elevated triglyceride levels, should the first line treatment be a fibrate or a statin, or should a combination be used? How safe is the combination therapy? Are there any particular side effects of cholesterol lowering in patients with diabetes, especially when more aggressive regimens are used? Data from the ongoing lipid lowering trials in diabetic populations will hopefully soon answer these questions.

**References:**


Mitteilungen aus der Redaktion

Besuchen Sie unsere
zeitschriftenübergreifende Datenbank

☑ Bilddatenbank  ☑ Artikeldatenbank  ☑ Fallberichte

e-Journal-Abo
Beziehen Sie die elektronischen Ausgaben dieser Zeitschrift hier.
Die Lieferung umfasst 4–5 Ausgaben pro Jahr zzgl. allfälliger Sonderhefte.
Unsere e-Journale stehen als PDF-Datei zur Verfügung und sind auf den meisten der marktüblichen e-Book-Readern, Tablets sowie auf iPad funktionsfähig.

☑ Bestellung e-Journal-Abo

Haftungsausschluss
Die in unseren Webseiten publizierten Informationen richten sich ausschließlich an geprüfte
und autorisierte medizinische Berufsgruppen und entbinden nicht von der ärztlichen Sorgfaltspflicht sowie von einer ausführlichen Patienten aufklärung über therapeutische Optionen
und deren Wirkungen bzw. Nebenwirkungen. Die entsprechenden Angaben werden von den Autoren mit der größten Sorgfalt recherchiert und zusammengestellt. Die angegebenen Do-
sierungen sind im Einzelfall anhand der Fachinformationen zu überprüfen. Weder die Autoren, noch die tragenden Gesellschaften noch der Verlag übernehmen irgendwelche Haftungsansprüche.

Bitte beachten Sie auch diese Seiten:
Impressum  Disclaimers & Copyright  Datenschutzverklärung